4D Molecular (FDMT) Therapeutics announced the publication of landmark preclinical data demonstrating the potential of the Company’s proprietary Therapeutic Vector Evolution platform, intravitreal ...
PER-001 demonstrated a favorable safety and tolerability profile in diabetic retinopathy and glaucoma SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical ...
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...
Twenty-four-week data from the Ph1/2a trial in glaucoma patients reveals PER-001 to be well-tolerated. Proof of concept is established with both strong functional and structural outcomes Glaucoma ...
PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma.
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results